{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T08:38:08Z","timestamp":1781167088190,"version":"3.54.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["PHP9001-20"],"award-info":[{"award-number":["PHP9001-20"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.clml.2021.07.034","type":"journal-article","created":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T09:23:13Z","timestamp":1627809793000},"page":"e65-e69","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Perceptions of Role in Treatment Decision Making and Understanding of Late Effects Among Hodgkin Lymphoma Survivors: Results From a National Survey HL Decision Making and Late Effects"],"prefix":"10.1016","volume":"22","author":[{"given":"Anita J.","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Murphy-Banks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth Ann","family":"Weidner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan K.","family":"Parsons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2021.07.034_bib0001","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.07.034_bib0002","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.07.034_bib0003","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S1470-2045(18)30784-8","article-title":"PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study","volume":"20","author":"Casasnovas","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2021.07.034_bib0004","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.07.034_bib0005","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1016\/S0140-6736(17)32134-7","article-title":"PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group","volume":"390","author":"Borchmann","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2021.07.034_bib0006","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/JCO.2015.63.1119","article-title":"US intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: southwest oncology group S0816","volume":"34","author":"Press","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.07.034_bib0007","series-title":"Cancer Statistics","year":"2020"},{"key":"10.1016\/j.clml.2021.07.034_bib0008","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1093\/annonc\/mds243","article-title":"Influence of new late effects on quality of life over time in Hodgkin lymphoma survivors: a longitudinal survey study","volume":"24","author":"Khimani","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2021.07.034_bib0009","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1200\/JCO.2003.01.044","article-title":"Health status and quality of life in patients with early-stage Hodgkin's disease treated on Southwest Oncology Group Study 9133","volume":"21","author":"Ganz","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.07.034_bib0010","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1200\/JCO.19.03160","article-title":"Health-related quality of life in patients with hodgkin lymphoma: a longitudinal analysis of the German Hodgkin Study Group","volume":"38","author":"Kreissl","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.07.034_bib0011","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/ijc.22739","article-title":"Increased health care utilization among long-term cancer survivors compared to the average Dutch population: a population-based study","volume":"121","author":"Mols","year":"2007","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clml.2021.07.034_bib0012","first-page":"2453","article-title":"Patient-reported distress in Hodgkin lymphoma across the survivorship continuum","volume":"27","author":"Troy","year":"2019","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clml.2021.07.034_bib0013","doi-asserted-by":"crossref","first-page":"4096","DOI":"10.1002\/cncr.32401","article-title":"Patient and caregiver perceptions of lymphoma care and research opportunities: a qualitative study","volume":"125","author":"Payne","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2021.07.034_bib0014","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2013a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"10.1016\/j.clml.2021.07.034_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: Building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"key":"10.1016\/j.clml.2021.07.034_bib0016","unstructured":"Brockelmann PJ. Patient and physician preferences for front-line treatment of advanced stage classical Hodgkin lymphoma in Germany, France and the United Kingdom."},{"key":"10.1016\/j.clml.2021.07.034_bib0017","doi-asserted-by":"crossref","first-page":"e27033","DOI":"10.1002\/pbc.27033","article-title":"Adolescent and young adult Hodgkin lymphoma: raising the bar through collaborative science and multidisciplinary care","volume":"65","author":"Kahn","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.clml.2021.07.034_bib0018","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/joim.12582","article-title":"Novel treatment concepts in Hodgkin lymphoma","volume":"281","author":"Glimelius","year":"2017","journal-title":"J Intern Med"},{"key":"10.1016\/j.clml.2021.07.034_bib0019","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.1182\/blood-2014-05-579193","article-title":"Current survivorship recommendations for patients with Hodgkin lymphoma: focus on late effects","volume":"124","author":"Ng","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.07.034_bib0020","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1080\/10428190802140873","article-title":"Cardiac morbidity following modern treatment for Hodgkin lymphoma: supra-additive cardiotoxicity of doxorubicin and radiation therapy","volume":"49","author":"Myrehaug","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2021.07.034_bib0021","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/bjh.16197","article-title":"Closing the survivorship gap in children and adolescents with Hodgkin lymphoma","volume":"187","author":"Castellino","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.07.034_bib0022","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1634\/theoncologist.2019-0172","article-title":"Contemporary outcomes for advanced-stage classical Hodgkin Lymphoma in the U.S.: analysis of surveillance, epidemiology, and end results database","volume":"24","author":"Guru Murthy","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2021.07.034_bib0023","unstructured":"Coalition L. 2018 Global Patient Survey on Lymphomas and CLL: Subtype Report Hodgkin Lymphoma 2018."},{"key":"10.1016\/j.clml.2021.07.034_bib0024","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1002\/cncr.31397","article-title":"Perceptions of future health and cancer risk in adult survivors of childhood cancer: a report from the childhood cancer survivor study","volume":"124","author":"Gibson","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2021.07.034_bib0025","doi-asserted-by":"crossref","first-page":"e27516","DOI":"10.1002\/pbc.27516","article-title":"Future health of AYA survivors","volume":"66","author":"Burkart","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.clml.2021.07.034_bib0026","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/jpepsy\/jsy102","article-title":"Knowledge of late effects risks and healthcare responsibility in adolescents and young adults treated for childhood cancer","volume":"44","author":"Lee","year":"2019","journal-title":"J Pediatr Psychol"},{"key":"10.1016\/j.clml.2021.07.034_bib0027","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1002\/cncr.31953","article-title":"Use of recommended posttreatment services for adolescent and young adult survivors of Hodgkin lymphoma","volume":"125","author":"Hahn","year":"2019","journal-title":"Cancer"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021003177?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021003177?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T09:49:28Z","timestamp":1778838568000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265021003177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S2152265021003177"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2021.07.034","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Perceptions of Role in Treatment Decision Making and Understanding of Late Effects Among Hodgkin Lymphoma Survivors: Results From a National Survey HL Decision Making and Late Effects","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2021.07.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}